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INTRODUCTION
Chronic graft-versus-host disease (CGVHD) is a late
complication of bone marrow transplantation (BMT) charac-
terized by a connective tissue–like disease that usually, but not
always, occurs more than 100 days following BMT. Clinically,
CGVHD may be manifested by involvement of the skin, oral
mucosa, gastrointestinal tract, eyes, liver, lungs, and joints
[1-4]. CGVHD develops in 30% to 60% of transplantation
survivors [5,6] and remains a major cause of morbidity and
mortality following allogeneic BMT. The major cause of
death in patients with CGVHD is infection due to continued
immunodeficiency [4,7]. Poor prognostic factors that have
been identified include thrombocytopenia (platelet count,
<100,000/µL), increased age, lichenoid skin pathology, liver
involvement, and progressive presentation of CGVHD [1,8]
(CGVHD developing before resolution of acute GVHD).
Prednisone alone or in combination with other immuno-
suppressive agents has been the standard treatment of
CGVHD [6,9]. Thalidomide has also been investigated as
an immunosuppressive agent active in the therapy of
CGVHD [5,10,11], primarily as a salvage agent in patients
with CGVHD resistant to other therapies or in high-risk
patients [10,11]. Thalidomide’s role in early therapy of
CGVHD is not yet established. This study was designed to
test the efﬁcacy of initial CGVHD therapy with thalidomide
in addition to cyclosporine and alternate-day prednisone in
an open label, prospective randomized trial. We report an
analysis of the response rate and survival in addition to a
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ABSTRACT
Chronic graft-versus-host disease (CGVHD) is a major cause of morbidity following allogeneic bone marrow trans-
plantation. Thalidomide is active in salvage therapy for high-risk or resistant CGVHD. In a prospective randomized
trial, we tested initial therapy with thalidomide. Patients with extensive CGVHD were randomized to receive either
cyclosporine and alternate-day prednisone (n = 27, no-thalidomide [no-thal] group) or cyclosporine, prednisone,
and thalidomide (200-800 mg/day; n = 27, thal group). Although most patients responded, initial therapy with thal-
idomide did not improve control of CGVHD. Response rates were 83% versus 89% at 2 months (P = .7), 88% versus
84% at 6 months (P > .8) and 85% versus 73% at 1 year (P = .5) in the thal and no-thal groups, respectively. Multi-
variate analysis revealed related donor transplant (odds ratio [OR] = 11.3; P =.03) and de novo or quiescent onset of
CGVHD (OR = 7.7; P =.04) to be significant predictors of good early response, whereas a platelet count of
≥100,000/µL was a significant predictor of good response (OR = 10.4; P =.04) at 1 year. Survival for the thal and no-
thal groups was similar at 1 year (66% versus 74%) and 2 years (66% versus 54%, P = .85). Multivariate analysis
revealed progressive onset CGVHD (relative risk [RR] = 4.2; P =.01), unrelated donor (RR = 5.7; P < .01), sex mis-
match (RR = 7.9; P < .01), and platelet counts of <100,000/µL (RR = 3.8; P = .01) as significant predictors of poorer
survival. These data suggest that despite a high response rate (79% response and 53% complete response) and
encouraging survival rates (70% at 1 year and 60% at 2 years), thalidomide offers no clinical benefit when incorpo-
rated into initial therapy for CGVHD. The value of thalidomide as salvage therapy requires further study.
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comparison of the frequency of complications including
infections in patients treated with and without thalidomide.
METHODS
Eligibility Criteria 
Patients who underwent allogeneic BMT at the Univer-
sity of Minnesota between September 1993 and April 1999
and developed extensive CGVHD were eligible for inclusion
in the trial. Extensive CGVHD was deﬁned as involvement
of 1 or more of the following organ systems: generalized skin
involvement (≥50% body surface area), liver involvement
(bilirubin, ≥3 mg/dL), positive Schirmer’s test, histologically
proven CGVHD of the oral mucosa, lung dysfunction with
bronchiolitis obliterans, and gastrointestinal involvement
with malabsorption and/or weight loss unexplained by other
etiologies. High-risk CGVHD was deﬁned as the presence
of 1 or more of 3 risk factors: progressive onset, platelet
count of <100,000/µL, and bilirubin level of ≥3 mg/dL.
Fifty-four patients were enrolled and randomized. Patients
were excluded if they had acute complications resulting in a
life expectancy of <1 month, were aged <2 or >60 years, had
an inability to take oral medications, had peripheral neuropa-
thy, or were pregnant or intended to become pregnant.
Patients were instructed about the hazards of birth defects
associated with prenatal exposure to thalidomide, and sexu-
ally active patients were required to use effective contracep-
tion while taking thalidomide. Before randomization,
patients were stratified into cohorts according to whether
they had received related donor or unrelated donor marrow.
Patients were randomly assigned to the thalidomide (thal)
arm or no-thalidomide (no-thal) arm. Blocked randomiza-
tion using block sizes of 4 and 6 was carried out. All patients
or their parents/guardians gave signed informed consent
according to guidelines approved by the University of Min-
nesota Institutional Review Board. Thalidomide was sup-
plied by Celgene Corporation (Warren, New Jersey) under
terms of a Food and Drug Administration Investigational
New Drug approval issued to the investigators (D.J.W.).
Treatment Plan 
Beginning at the time of randomization, all patients
received initial therapy with high-dose methylprednisone.
Methylprednisone was given at a dose of 15 mg/kg as an
intravenous injection weekly for 8 weeks. Patients assigned
to the thal arm received prednisone, cyclosporine, and thal-
idomide from the time of randomization. Those assigned to
the no-thal arm received prednisone and cyclosporine. The
initial dosage of thalidomide was 50 mg 4 times a day in
adult patients and 0.75 mg/kg 4 times a day in pediatric
patients. Dosage was increased as tolerated at 2 to 4 week
intervals to a maximum of 200 mg 4 times a day in adults
and 3 mg/kg 4 times a day in pediatric patients. Thalido-
mide levels were not monitored. Prednisone was given at a
dosage of 0.5 mg/kg by mouth on alternate days and cyclo-
sporine was started at 6.25 mg/kg by mouth twice daily (or
1.5 mg/kg intravenously twice daily) with the dosage being
modiﬁed to maintain trough levels >200 ng/mL. In patients
with no response to the initial 8 weeks of therapy or with
disease progression after initial stabilization or response,
methylprednisone was given at a dosage of 15 mg/kg per
day intravenously for 5 days, and oral prednisone was
increased to 1 mg/kg per day by mouth for 6 weeks, then
tapered over a 3-month period to 0.5 mg/kg per day on
alternate days. Therapy was continued until 9 months fol-
lowing the last clinical evidence of active CGVHD, followed
by a taper over 2 to 3 months. In persistent or refractory
disease, crossover to the thal arm was permitted, but only
after 6 months of assigned therapy. All subjects randomized
were analyzed as intention-to-treat in their assigned treat-
ment groups.
Measurement of Response 
Patients were evaluated for response to therapy at
2 months, 6 months, and 1 year from randomization.
Because patients did not always return to the transplantation
center on the scheduled dates, window periods for evalua-
tion were used to maximize the completeness of evalua-
tion. For the 2-month visit, the evaluation window period
was between 1 and 3 months from randomization. For the
6-month and 1-year visits, window periods of 4 to 9 months
and 9 to 16 months, respectively, were used. All patients
included in the study were randomized at least 6 months
prior to study termination. The median follow-up of surviv-
ing patients was 22 months (range, 6-58 months).
Response to therapy was graded as complete response
(CR), defined as resolution of all signs and symptoms of
CGVHD. Partial response (PR) was defined as improve-
ment in 1 or more organs of involvement and no evidence of
worsening in any organ. Flare was deﬁned as PR or CR fol-
lowed by worsening of CGVHD to a severity less than that
at baseline evaluation. No response was defined as either
progression of CGVHD to worse than at baseline evalua-
tion or no improvement in CGVHD after 6 months of ther-
apy. Prevalence of CGVHD was deﬁned as the proportion
of all patients with active CGVHD among surviving
patients. Improvement or worsening of disease was deter-
mined through both subjective and objective criteria. Sub-
jective criteria were symptomatic changes in cough, dyspnea,
anorexia, nausea, vomiting, diarrhea, arthralgia, or dry eyes.
Objective criteria included physical exams of skin and oral
mucosa, weight measurements, liver function tests, pul-
monary function tests, Schirmer’s test, biopsies, and radio-
logical studies. Patients who had no response or ﬂare before
they died were included at subsequent time points as nonre-
sponders or treatment failures.
STATISTICAL ANALYSIS
The study was designed as a prospective randomized
trial. The expected high incidence of complications caused
by thalidomide (chieﬂy constipation and somnolence) pre-
cluded blinding of the study drug, so no placebo therapy
was used. However, data collection, grading of response,
and, importantly, statistical analysis were performed without
knowledge of treatment-group assignment. Analysis of
response and survival were performed before any examina-
tion of side effects to maintain the blinding during analysis.
Prestudy Sample Size and Power Projections 
The primary endpoint of the study was response to
treatment; the secondary endpoint was overall survival. To
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detect a 20% difference in response (presuming a response
rate of 65% in the control arm) with 80% power at α of
0.05, a sample size of 134 patients (half randomized to each
arm) was needed. However, after accrual of 54 randomized
patients, this blinded interim analysis was performed.
Because both treatment arms had response rates higher than
projected, with only a 12% difference in response between
the 2 treatment arms, recalculation of the sample size to
detect a >20% difference would have necessitated an added
enrollment of 104 patients. This study size was unworkable,
so the study was closed.
Response to Therapy
Pearson’s chi-square test was employed to compare the
proportion of subjects who responded to therapy with those
who did not (complete and partial response versus no
response and ﬂare) at 2 months, 6 months, and 1 year after
randomization. The Fisher exact test was used when the
expected cell count was less than 5.
Predictors of Response 
Thirteen potential predictors were evaluated. These
included treatment arm, recipient age at transplantation, sex
of recipient and donor, cytomegalovirus serologic status of
recipient and donor, type of transplant (allogeneic sibling
versus unrelated donor), HLA mismatch, prior presence and
clinical grade of acute GVHD, onset of CGVHD (de novo,
progressive, quiescent), organ involvement with CGVHD
(eyes, mouth, skin, lungs, gastrointestinal tract, liver), white
blood cell count, platelet count, and serum bilirubin and
alanine aminotransferase levels at baseline. Pearson’s chi-
square test was employed in the univariate analyses to com-
pare the proportion of subjects with response to therapy
within each category of potential predictors. Multivariate
logistic regression was used to evaluate the independent
effect of study variables on treatment response. A stepwise
regression with forward selection was used. A variable had
to be signiﬁcant at the 0.10 level before it could enter into
the model and had to be signiﬁcant at the 0.15 level for it to
remain in the regression model.
Survival 
Patient survival was determined using the Kaplan-Meier
[12] estimation with 95% conﬁdence intervals derived from
standard errors. Patients were censored at the date of last
contact. Comparison of survival between the 2 treatment
groups was carried out using Kaplan-Meier plots and log-
rank tests [12]. 
Predictors of Mortality 
Potential factors associated with effects on mortality
were studied. The Kaplan-Meier product limit method [12]
was used to compare survival in the subsets, and the Cox
regression model [13] was used to assess the independent
effect of the predictors on survival as well as any potential
confounding of the effect of the randomized treatment. A
stepwise regression with forward selection was used with a
signiﬁcance level of P = .10 being needed to enter into the
model and a signiﬁcance level of P = .15 to remain in the
model. Recipient age was not included in the model because
of nonproportionality, and the results were stratified by
recipient age. Acute GVHD (grade III-IV) was excluded
from the model because of colinearity between progressive
onset and acute GVHD.
Complications After Transplantation 
Complications studied included hypertension, hyper-
glycemia requiring treatment, constipation, somnolence,
seizures, neuropathy, thrombotic thrombocytopenic purpura
(TTP), avascular necrosis, and infections. Pearson’s chi-
square test was employed to compare the proportion of
patients with complications in the 2 treatment groups.
Infections Following BMT 
To account for multiple events, density incidence was
used to describe the total rate of infections. Density inci-
dence was defined as the total number of infections per
1000 patient-days. Statistical comparison of the density
incidence was done by using the Mantel-Haenszel chi-
square test [14] for person-days data.
RESULTS
The clinical characteristics of the 54 patients are shown
in Table 1. There were 27 patients in each treatment group.
Patients randomized to receive thalidomide were slightly
older than those who did not receive it (median age, 44 versus
37 years; P = .01), but there were no signiﬁcant differences in
pretransplantation diagnoses, types of transplant donors,
conditioning regimens, prophylaxis for acute GVHD, pres-
ence or stage of acute GVHD, or pattern of onset and organ
involvement with CGVHD. Overall, 27 patients had high-
risk CGVHD. Nine patients (5 receiving thalidomide and
4 receiving no thalidomide) had progressive onset of
CGVHD. Six patients (3 in each group) had hyperbilirubine-
mia, and 22 patients (10 in the no-thal group and 12 in the
thal group) had signiﬁcant thrombocytopenia at the time of
diagnosis of CGVHD. Eight of the 27 patients (4 in the thal
group, 4 in the no-thal group) had 2 high-risk factors,
whereas 3 patients (1 in the thal group, 2 in the no-thal
group) had all 3 high-risk factors at diagnosis of CGVHD.
Response to Therapy 
As shown in Table 2, the response to combination
immunosuppressive therapy was evaluated at 2 months,
6 months,  and 1 year from randomization. Of the
54 patients enrolled, the number of patients evaluable for
response was 51 at 2 months, 49 at 6 months, and 42 at
1 year. Three patients in the thal group died within 1 month
of starting therapy and were unevaluable. Two patients in
the no-thal group relapsed and died and thus had no
response assessed at 6 months and 1 year. Two additional
patients in the thal group died and were not evaluable at
1 year. Five patients (2 in the thal group and 3 in the no-thal
group) have not as yet completed 1 year of therapy.
Complete and partial responses were observed in 86%,
85%, and 79% of the patients at 2 months, 6 months, and
1 year, respectively. At 1 year, 22 patients (52%) had a CR.
Response rates were similar in both treatment groups at all
3 time points. Clinical response rates (CR + PR) in the thal
and no-thal groups were similar at 2 months (83% versus
89%, P = .7), 6 months (88% versus 84%, P > .8) and 1 year
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(85% versus 73%, P = .5). In patients with high-risk disease,
response rates were similar over time and did not differ in
the 2 treatment groups (Table 2), although a few more
patients in the no-thal group had either no response or ﬂare
of CGVHD at their 6-month and 1-year evaluations.
Predictors of Response 
We analyzed 13 clinical factors as potential predictors of
response at 2 months and 1 year (Table 3). Similar ﬁndings
were observed at 6 months (not shown). Use of thalidomide
was not associated with more frequent responses. In univari-
ate analysis, more frequent response to therapy was seen in
recipients of related donor transplants and in patients with
de novo/quiescent onset of CGVHD. Recipients of related
donor transplant had more frequent early responses (94%
versus 72%, P = .08). More frequent early responses were
also seen in patients with de novo and quiescent onset of
CGVHD (91% versus 63% at 2 months, P = .06 and 84%
versus 40% at 1 year, P = .05, respectively). Involvement of
the skin also identified patients with more frequent
responses at 2 months and 1 year.
In the multivariate analysis (Table 4), related donor
transplant (odds ratio [OR] = 11.3; P = .03) and de novo or
quiescent onset of disease (OR = 7.7; P = .04) were signiﬁ-
cant predictors of more frequent early (2 months) response.
A platelet count of >100,000/µL was a signiﬁcant predictor
of more frequent late (1 year) response (OR = 10.4; P = .04).
Involvement of skin was an independently significant pre-
dictor of more frequent early as well as late responses (OR =
9.7, P = .03 and OR = 25, P < .01, respectively). Randomiza-
tion to thalidomide had no signiﬁcant impact on response to
therapy at any time point.
Of note, patients with lung involvement also showed a
high response. Eight of 10 patients in the thal group and
7 of 9 patients in the no-thal group showed a clinical
response at 1 year.
Survival 
Thalidomide therapy for CGVHD did not lead to
improved survival. After a median follow-up of 22 months
(range 6-58 months), it was determined that at 2 years thal-
idomide-treated patients had survival rates similar to those
of the control cohort (Figure 1) (range, 66% and 54%,
respectively, P = .85) with no deaths observed in surviving
patients beyond 2 years. Patients with high-risk disease had
an actuarial survival of 53% (range, 33%-73%) 1 year after
transplantation and 44% (range, 21%-67%) 2 years after
transplantation. Therapy with thalidomide did not alter sur-
vival time in the higher-risk subgroup (2-year survival rate
of 26% versus 28%, respectively, in the high-risk thal and
no-thal groups, respectively, P = .5).
Overall, 19 patients died, 10 in the no-thal group and
9 in the thal group (P = .8). Three patients in the thal group
died within 1 month of starting therapy because of infec-
tious complications. Four patients in the thal group and
8 patients in the no-thal group died with severe unrespon-
sive CGVHD. Two patients relapsed, both in the no-thal
group. One patient in the thal group developed progressive
multifocal leukoencephalopathy and 1 other patient in the
thal group with severe continuing pancytopenia died of bac-
terial and fungal infections after 1 year of therapy.
Table 1. Clinical Characteristics at Study Entry*
Thal Group, No-Thal
n (%) Group, n (%) P
Patient Demographics
No. of patients 27 (50) 27 (50)
Diagnosis
Acute leukemia 12 (44) 12 (44) .39
CML 12 (45) 11 (41)
Other malignancies 2 (7) 3 (11)
Nonmalignant Diseases 1 (4) 1 (4)
Age, y
Median (range) 44 (17-60) 37 (12-50) .01
<20 1 (4) 5 (19)
20-29 2 (7) 5 (19)
30-39 7 (26) 5 (19)
≥40 17 (63) 12 (43)
Donor/recipient sex mismatch
Male recipient with female donor 5 (19) 4 (15) >.8
Others 17 (63) 19 (70)
Donor/recipient CMV 17 (63) 19 (70) .77
sero-status (either or both +)
Type of transplant
Sibling donor 18 (67) 16 (59) .77
Unrelated donor 9 (33) 11 (41)
HLA mismatch (related donor) 3 (17) 1 (6) .60
HLA mismatch (unrelated donor) 1 (11) 4 (36) .31
Conditioning regimens
TBI + cyclophosphamide 25 (92) 23 (85) .66
Others 2 (8) 4 (15)
Prophylaxis for acute GVHD
Methotrexate + cyclosporine 20 (74) 22 (81) .50
T-cell depletion 5 (19) 4 (15)
Others 2 (7) 1 (4)
Acute GVHD
Grade II-IV acute GVHD 18 (67) 20 (74) .55
Grade III-IV acute GVHD 7 (26) 6 (22) .75
Characteristics of CGVHD
Onset of CGVHD
De novo 6 (22) 4 (15) >.8
Quiescent 16 (59) 19 (70)
Progressive 5 (19) 4 (15)
Time to treatment (days after 190 (63-794) 194 (75-812) >.8 
transplant) median (range)
Organ involvement
Skin 16 (60) 21 (78) .14
Oral 24 (89) 21 (78) .27
Liver 12 (44) 9 (33) .4
Gastrointestinal 21 (78) 17 (63) .23
Lungs 9 (33) 14 (52) .16
Eyes 13 (48) 9 (33) .26
High-risk CGVHD† 14 (52) 13 (48%) .8
Standard risk 13 (48%) 14 (52%)
Platelet count, 118 (17-352) 105 (39-384) .8
median (range)
WBC count, 5150 (2100- 3900 (1400- .18
median (range) 15,000) 8400)
Bilirubin ≥3 mg/dL 3 (11) 3 (11) >.8
Alanine aminotransferase 4 (15) 5 (19) .71 
>250 units/dL
*P values reﬂect chi square or the Fisher exact test comparisons between
treatment groups. CML indicates chronic myelogenous leukemia; CMV,
cytomegalovirus; TBI, total body irradiation; GVHD, graft-versus-host
disease; plts, platelet count; WBC, white blood cell count. 
†High-risk CGVHD was deﬁned as presence of either progressive
onset of disease, bilirubin ≥3 mg/dL or platelet count of <100,000/µL.
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Table 2. Patient Evaluability and Frequency of Response to Therapy*
2-Month Follow-up 6-Month Follow-up 1-Year Follow-up
Thal No-Thal P Thal No-Thal P Thal No-Thal P
All patients
Evaluable patients 24 27 24 25 20 22
CR, n (%) 2 (8) 2 (7) 4 (17) 7 (28) 10 (50) 12 (55)
PR, n (%) 18 (75) 22 (81) 17 (71) 14 (56) 7 (35) 4 (18)
CR+PR, n (%) 20 (83) 24 (89) .7 21 (88) 21 (84) >.8 17 (85) 16 (73) .5
NR+Flare, n (%) 4 (17) 3 (11) 3 (12) 4 (16) 3 (15) 6 (27)
High-risk CGVHD patients
Evaluable patients 11 13 11 12 8 9
CR, n (%) 1 (9) 1 (8) 2 (18) 1 (8) 3 (38) 3 (33)
PR, n (%) 8 (73) 9 (69) 8 (73) 7 (59) 4 (50) 1 (11)
CR+PR, n (%) 9 (82) 10 (77) >.8 10 (91) 8 (67) .3 7 (88) 4 (44) .1
NR+Flare, n (%) 2 (18) 3 (23) 1 (9) 4 (33) 1 (12) 5 (56)
*P value represents Pearson’s chi-square comparisons between patients with CR+PR versus NR+Flare at 2 months, 6 months, and 1 year.
CR indicates complete response; PR, partial response; NR, no response; CGVHD, chronic graft-versus-host disease.
Table 3. Predictors of Response: Univariate Analysis*
2-Month Follow-up 1-Year Follow-up
No. of Evaluable No. of Evaluable
Predictor Patients Responders, % P Patients Responders, % P
All patients 51 86 42 79
Treatment group
Thalidomide 24 83 .7 20 85 .4
No thalidomide 27 89 22 73
Age
≥30 years 38 89 .4 30 80 .7
<30 years 13 77 12 75
Sex mismatch
Male recipient:female donor 7 100 .5 6 50 .1†
Others 44 84 36 83
Type of Transplant
Unrelated donor 18 72 .08 15 67 .2
Related donor 33 94 27 85
Acute GVHD
Grade III-IV 12 75 .3 9 67 .4
Grade 0-II 39 90 33 82
Onset
Progressive 8 63 .06 5 40 .05†
Denovo + quiescent 43 91 37 84
Organ involvement with CGVHD
Skin 34 94 .03 27 93 <.01†
None 17 71 15 53
Oral 43 91 .2 37 81 .3
None 8 75 5 60
Eye 22 91 .7 18 78 >.8
None 29 83 24 79
Lungs 21 86 >.8 19 79 >.8
None 30 87 23 78
Gastrointestinal 37 86 >.8 28 75 .7
None 14 86 14 86
Liver 21 81 .4 16 75 .7
None 30 90 26 81
Platelets <100,000/µL 19 79 .4 13 62 .1†
Platelets ≥ 100,000/µL 32 91 29 86
Bilirubin ≥3 mg/dL 5 60 .13 4 50 .1†
Bilirubin <3 mg/dL 46 89 38 82
*Response refers to CR or PR at the time period shown. P values reﬂect chi-square tests of signiﬁcance. GVHD indicates graft-versus-host dis-
ease; CGVHD, chronic GVHD.
†Value was entered into subsequent multivariate analysis. 
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Predictors of Mortality 
In univariate analysis, several factors were associated
with poor survival. Type of transplant (unrelated donor ver-
sus related donor, P = .05), grade III-IV acute GVHD (P =
.05), sex mismatch (male recipient with female donor versus
other sex combinations, P < .01), progressive onset of dis-
ease (versus de novo and quiescent, P = .01), platelet count
of <100,000/µL (P < .01), and bilirubin level of ≥3 mg/dL
(P = .03) were each signiﬁcant predictors of poor outcome
(Figure 2).
In the multivariate analysis (Table 5), progressive onset
of disease (relative risk [RR] = 4.2; P = .01), unrelated donor
transplant (RR = 5.7; P < .01), male recipient:female donor
(RR = 7.9; P < .01), and platelet count of <100,000/µL (RR =
3.8; P = .01) were independently significant predictors of
poor survival. Treatment with thalidomide had no indepen-
dently signiﬁcant impact on survival.
Prevalence of CGVHD 
Following the onset of randomized therapy, we evalu-
ated the prevalence (persistence of active CGVHD in sur-
viving patients) of CGVHD over time. Prevalence assessment
incorporates both ﬂares and persistence of CGVHD and as
prevalence falls it reﬂects a clinical cure of CGVHD. The
prevalence of CGVHD decreased to 82% at 6 months, 35%
at 1 year, and 28% at 2 years from randomization. Resolu-
tion of CGVHD occurred at the same frequency and pace
in patients assigned to the thal or no-thal group, resulting in
prevalence of 81% versus 83% at 6 months, 36% in both
groups at 1 year, and 25% versus 30% at 2 years, respec-
tively (P > .8) (Figure 3).
Complications 
The anticipated complications of thalidomide, constipa-
tion (52% versus 11% in the no-thal group; P < .01), sleepi-
ness (63% versus 0%, P < .01), and neuropathy (13 patients,
48% versus 3 patients, 11%; P < .01) were more common in
the thal group (Table 6). Six patients (22%) had signiﬁcant
neuropathy requiring discontinuation of thalidomide. Thal-
idomide was continued in patients with nonprogressive
paresthesias, although these patients were monitored fre-
quently. Fewer patients in the thal group than in the no-thal
group had hypertension (30% versus 56%; P = .05). Hyper-
glycemia, TTP/hemolytic uremic syndrome, seizures, and
avascular necrosis occurred with similar frequency in the
thal and no-thal groups.
Infections 
As shown in Figure 4, more frequent infections were
observed in patients not receiving thalidomide. The density
incidence of all infections showed a trend toward more
infections in the no-thal group (6.6 per 1000 person-days
versus 4.6 per 1000 person-days; RR for thal group = 0.7;
P = .07). Bacterial infections were more frequent in the no-
thal group across all time periods (P = .04). Across all time
periods, similar incidence densities of viral and fungal infec-
tions were seen in the 2 treatment groups.
Compliance With Thalidomide Therapy 
Of 27 patients assigned to the thal group, 13 of 18 sur-
viving have remained on therapy for 1 year. One other
patient continues on therapy at 6 months. Three patients
stopped thalidomide within 3 months because of intolerable
side effects (constipation, sleepiness, and neuropathy). Three
other patients stopped treatment between 4 and 6 months
because of neuropathy. One patient stopped both thalido-
mide and cyclosporine at 5 months after he developed TTP.
After the initial 6 months of therapy without thalidomide,
2 patients in the no-thal group crossed over to add thalido-
mide along with continuing cyclosporine and prednisone.
One of these patients had no further response and died
15 months later of bacterial and fungal infections. The sec-
ond patient started thalidomide and achieved a CR at 1 year.
He continued on combination therapy until 17 months, but
died of infections at 23 months after initial randomization.
Table 4. Predictors of Response: Multivariate Analysis*
2-Month Follow-up 1-Year Follow-up
Predictor OR (CI) P OR (CI) P
Related donor versus URD transplant 11.3 (1.2-109) .03 8.0 (0.8-83.6) .1
De novo + quiescent versus progressive disease onset 7.7 (1.8-67) .04 5.6 (0.3-93.6) .2
Platelets ≥100,000/µL versus <100,000/µL 5.3 (0.5-52) .2 10.4 (1.02-105) .04
Skin versus no skin involvement 9.7 (1.2-81.9) .03 25 (2-250) <.01
Treatment arm (no-thal versus thal) 4.1 (0.4-43.8) .28 0.7 (0.09-5.9) .6
*Logistic regression showing the independent odds ratio (OR) and 95% conﬁdence interval (CI) favoring complete response or partial response
at the evaluation period shown. URD indicates unrelated donor; thal indicates thalidomide.
Figure 1. Survival after randomization to initial therapy of chronic
graft-versus-host disease with and without thalidomide. P value repre-
sents log-rank tests of signiﬁcance between the 2 treatment groups.
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DISCUSSION
Previous reports have suggested that thalidomide has
substantial clinical activity in treatment of CGVHD,
although it has usually been administered as salvage therapy
[5,10,11,15]. The current trial is the first prospective ran-
domized study of thalidomide as initial therapy in patients
with CGVHD. Our study was designed to compare the rate
and completeness of response as well as survival in both
treatment groups. Previous studies of thalidomide or ran-
domized assessments of cyclosporine and prednisone have
been conducted on high-risk groups or in patients refractory
to conventional treatment [10,11,16]. In the current trial
testing the utility of thalidomide as initial therapy of
CGVHD, we observed a high overall response rate of 79%
in the entire cohort (85% in the thal group versus 73% in
the no-thal group) and a response rate of 66% (88% in the
thal group and 44% in the no-thal group) in patients with
high-risk CGVHD at 1 year that is similar to that reported
for previous studies of initial CGVHD therapy. Sullivan et
al. reported response rates in patients receiving alternating-
day cyclosporine and prednisone of 56% and 71% in high-risk
and refractory patients, respectively [16]. Using thalidomide,
Vogelsang et al. [11] observed 38% and 78% response in
high-risk and refractory patients, respectively. Parker et al.
[10] reported only a 20% response to thalidomide in refractory
Figure 2. Survival after randomization to initial therapy of chronic graft-versus-host disease (CGVHD) (as in Figure 1). D, Cohorts are divided by
number of high-risk factors at onset of CGVHD. Factors included those shown in A, B, and C plus sex mismatch.
Table 5. Factors Associated With Poor Survival After CGVHD: 
Multivariate Analysis*
Predictor RR (CI) P
Progressive onset 4.2 (1.3-13.2) .01
Unrelated donor transplant 5.7 (1.8-17.7) <.01
Sex mismatch (male recipient:female 7.9 (2.3-16.3) <.01
donor versus others)
Platelets <100,000/µL 3.8 (1.3-10.8) .01
Treatment (thalidomide versus no 0.62 (.38-1.71) .4
thalidomide)
*Results are stratiﬁed by recipient age (not included in the analysis
because of nonproportionality). Shown is the relative risk (RR) (95%
conﬁdence interval [CI]) of mortality following therapy for chronic graft-
versus-host disease (CGVHD).
Figure 3. Prevalence of chronic graft-versus-host disease over time in
patients treated with immunosuppression including thalidomide (thal)
(black bars) or no thalidomide (no thal) (gray bars). P > .8 for compar-
isons at all time points.
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patients. However, this study used a more stringent deﬁni-
tion of response, including only patients with sustained
responses without later progression on tapering medications.
We assessed both early (2 months) as well as late (1 year)
responses. Because patients living in other geographic areas
were followed at local health care facilities and returned
only infrequently for follow-up, window periods were used
to maximize completeness of evaluation. We observed a
high frequency of early response at 2 months (83% and 89%
in thal and no-thal groups, respectively). All patients in the
current trial received additional initial therapy with high-
dose methylprednisone weekly for 8 weeks. This initial
intensive therapy with high-dose steroids might be an
important contributor to this high initial response rate. In
addition, we observed an overall CR rate at 1 year of 50% in
the thal group versus 55% in the no-thal group, a higher
rate than has been previously reported. Our CR rates in
patients with high-risk CGVHD are similar to previous
studies (38% in the thal group and 33% in the no-thal
group respectively). Sullivan et al. [16] described 33% and
19% CR in high-risk and refractory groups without thalido-
mide, respectively, whereas Vogelsang et al. [11] reported
30% and 33% CR, respectively, using thalidomide.
After 2 years, 66% and 54% of patients were alive in the
thal and no-thal groups, respectively. These survival rates
are similar to rates of survival after CGVHD reported by
Vogelsang et al. [11] (64%), Sullivan et al. [16] (51% and
67% in high-risk and refractory patients, respectively), and
Parker et al. [10] (53%).
We evaluated potential prognostic factors associated with
improved response or survival. Among these factors, progres-
sive onset of disease, unrelated donor transplant, and platelet
count of <100,000/µL were independent predictors of both
poor response and worse survival. Male recipient:female
donor was also an independent predictor of higher mortality.
These ﬁndings are similar to conclusions from previous stud-
ies [1,8,17]. Data clearly outlining the response to CGVHD
after unrelated donor transplantation is limited. In the 3 stud-
ies previously cited, only Parker et al. [10] had included 11%
of patients receiving an unrelated donor transplant. In this
study (including nearly 40% unrelated donor transplant
recipients), we observed that patients receiving unrelated
donor transplants have signiﬁcantly poorer response and sur-
vival rates, with or without thalidomide.
The persistence of CGVHD including flares and later
responses is reﬂected in the overall prevalence of the disease
over time. The prevalence of CGVHD decreased from 94%
at 2 months to 28% at 2 years, with 72% of the surviving
patients cured of CGVHD at 2 years. However, no difference
was seen between the 2 treatment groups at any time points.
Table 6. Complications of Therapy*
Complications Thal Group, n (%) No-Thal Group, n (%) P
Hypertension 8 (30) 15 (56) .05
Diabetes mellitus 3 (11) 6 (22) .3
Constipation 14 (52) 3 (11) <.01
Sleepiness 17 (63) 0 (0) <.01
Seizures 1 (4) 0 (0) >.8
Neuropathy 13 (48) 3 (11) <.01
TTP/HUS 2 (7) 1 (4) >.8
Avascular necrosis 1 (4) 3 (11) .6
*The frequency of complications in both treatment groups is
shown. Those requiring therapy (hypertension, hyperglycemia,
seizures, thrombotic thrombocytopenic purpura/hemolytic uremic syn-
drome [TTP/HUS]) or treatment modiﬁcation (neuropathy) are noted.
P values represent chi-square tests of signiﬁcance.
Figure 4. Infections complicating chronic graft-versus-host disease. Shown are the incidence density of bacterial, viral, and fungal infections
expressed as infections per 1000 patient-days (p-d) of follow-up of living patients. The thalidomide treated group (black bars) and the no thalido-
mide group (gray bars) are shown compared over time. D, Comparison of assessments of infections over the 16-month observation period. P values
represent Mantel-Haenszel tests of signiﬁcance.
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The dose of thalidomide that we tested was based largely
on previous clinical studies rather than on the drug’s pharma-
cokinetic evaluation. A clearly deﬁned therapeutic drug level
is not known, and we were unable to monitor thalidomide
levels in this study. About 70% of patients had gastrointesti-
nal involvement and drug absorption might have been a prob-
lem in these patients, even though they had no apparent
differences in the observed absorption-dependent complica-
tions of somnolence and constipation (data not shown). How-
ever, the appropriate dose in this subset of patients is not
known. Future trials with thalidomide might incorporate dos-
ing according to drug levels to directly address this concern.
Overall, we observed no beneﬁt of adding thalidomide
to cyclosporine and alternate-day administration of pred-
nisone as initial therapy. No increase in overall response,
complete response, or survival time was seen with the addi-
tion of thalidomide. The prevalence, pace of response, and
complete resolution of CGVHD was not altered by the
addition of thalidomide. Although this study was terminated
early due to a higher than expected response in both treat-
ment arms, only a much larger trial could be sufficiently
powered to detect any potential unobserved benefit from
therapy with thalidomide.
Thalidomide has a number of side effects, particularly
constipation and somnolence, which are seldom severe and
are reversible when treatment is interrupted. Apart from
the well-known teratogenic side effects, the most important
side effect is the occurrence of peripheral neuropathy
[5,15]. Peripheral neuropathy occurred frequently in our
study (48%) and necessitated discontinuation of the drug in
6 patients (22%).
Infections are frequent secondary complications of
CGVHD [7,18]. Somewhat lower infection incidence was
observed in the thal group despite similar rates of response
and prevalence of CGVHD over time. This observation
requires conﬁrmation and further study to assess its clinical
importance.
We conclude that thalidomide offers no apparent clinical
beneﬁt when incorporated into initial therapy of CGVHD.
Thalidomide’s previously reported activity as salvage therapy
suggests that a controlled study in patients with CGVHD
resistant to prednisone and cyclosporine is still needed.
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